drugset / Trial / NCT00463879
Galantamine for Cognitive Deficits in Schizophrenia
Phase 2/3
Completed
21 enrolled
Yale University
National Alliance for Research on Schizophrenia and Depression · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the acute effects of the nicotinic receptor allosteric modulator galantamine (0, 4 and 8 mg) on neurocognitive function in schizophrenic smokers (n=20) versus schizophrenic nonsmokers (n=10) in an outpatient human laboratory setting.
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galantamine | Small molecule | 0 mg | — |
| Subject | Galantamine | Small molecule | 4 mg | — |
| Subject | Galantamine | Small molecule | 8 mg | — |